|
Today's Headlines
Infections caused by a specific type of antibiotic-resistant bacteria are on the rise in US children, according to study published in the Journal of the Pediatric Infectious Diseases Society. While still rare, the bacteria are increasingly found in children of all ages, especially those aged 1 to 5 years old, raising concerns about dwindling treatment options. » Full article
|
|
Local infiltration with long-acting liposome bupivacaine (Exparel) as part of a non-narcotic multimodal pain management regimen for joint replacement surgeries, meaningfully improves patient and hospital economic outcomes, according to new data presented at the 81st annual meeting of the American Academy of Orthopaedic Surgeons. » Full article
|
Continuing Education
This month's article is the second in a new year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease.
From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
This month, the professional development activity is “MTM essentials for management of CAD and PAD,” a knowledge-based activity worth up to 2 credits.
The goal of this activity is to review therapeutic strategies pharmacists can utilize to improve patient care in the management of coronary artery disease and peripheral artery disease.
To read and print the article with TEST QUESTIONS, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
|
EDITOR'S PICK
Ever since the passage of the Orphan Drug Act (ODA) 30 years ago, more than 350 orphan drugs have been developed to help treat patients with rare diseases. FDA has provided many incentives to biotech companies—such as shorter clinical trials, longer patent times, and tax breaks—making it an attractive target for investment for early-stage and emerging growth companies. » Full article
|
|
Like
Tweet
